CA2265523A1 - Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof - Google Patents

Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof Download PDF

Info

Publication number
CA2265523A1
CA2265523A1 CA002265523A CA2265523A CA2265523A1 CA 2265523 A1 CA2265523 A1 CA 2265523A1 CA 002265523 A CA002265523 A CA 002265523A CA 2265523 A CA2265523 A CA 2265523A CA 2265523 A1 CA2265523 A1 CA 2265523A1
Authority
CA
Canada
Prior art keywords
seq
pylori
polypeptide
nucleic acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002265523A
Other languages
English (en)
French (fr)
Inventor
Douglas Smith
Richard A. Alm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2265523A1 publication Critical patent/CA2265523A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002265523A 1996-10-28 1997-10-28 Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof Abandoned CA2265523A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US73915096A 1996-10-28 1996-10-28
US08/739,150 1996-10-28
US75973996A 1996-12-06 1996-12-06
US08/759,739 1996-12-06
US89192897A 1997-07-14 1997-07-14
US08/891,928 1997-07-14
PCT/US1997/019575 WO1998018323A1 (en) 1996-10-28 1997-10-28 Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof

Publications (1)

Publication Number Publication Date
CA2265523A1 true CA2265523A1 (en) 1998-05-07

Family

ID=27419246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265523A Abandoned CA2265523A1 (en) 1996-10-28 1997-10-28 Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof

Country Status (19)

Country Link
EP (1) EP0973394A4 (ar)
JP (1) JP2001504329A (ar)
KR (1) KR20000052831A (ar)
CN (1) CN1235513A (ar)
AR (1) AR009600A1 (ar)
AU (1) AU734052B2 (ar)
BR (1) BR9712587A (ar)
CA (1) CA2265523A1 (ar)
EE (1) EE9900176A (ar)
ID (1) ID22065A (ar)
IL (1) IL129397A0 (ar)
IS (1) IS5005A (ar)
NO (1) NO991995L (ar)
NZ (1) NZ334568A (ar)
PL (1) PL333169A1 (ar)
SA (1) SA98180918A (ar)
SK (1) SK34699A3 (ar)
TR (1) TR199900940T2 (ar)
WO (1) WO1998018323A1 (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
NZ269124A (en) * 1993-07-27 1997-06-24 Csl Ltd Vaccine comprising helicobacter antigens and its use in treating such infections
DE19730425A1 (de) 1997-07-16 1999-01-21 Henkel Teroson Gmbh Heißhärtende wäschefeste Rohbau-Versiegelung
EP1108033A2 (en) * 1998-07-27 2001-06-20 Aventis Pasteur Limited $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
SE9901548D0 (sv) * 1999-04-29 1999-04-29 Astra Ab Helicobacter pylori antigens
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
AUPQ347199A0 (en) * 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
EP2298875B1 (en) 2000-03-08 2015-08-12 Novozymes A/S Variants with altered properties
GB0010370D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
GB0010371D0 (en) * 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
EP2695938B1 (en) * 2011-03-17 2016-11-30 National UniversityCorporation Mie University Antibody production method
JP6959937B2 (ja) * 2015-12-14 2021-11-05 テクニシェ ユニバーシタット ミュンヘン ヘリコバクターピロリワクチン
CN115724922B (zh) * 2022-07-19 2023-08-22 四川大学华西医院 一种幽门螺杆菌疫苗重组蛋白抗原TonB及其制备方法与应用
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9300139L (sv) * 1993-01-19 1994-07-20 Medicarb Ab Framställning av ett nytt läkemedel

Also Published As

Publication number Publication date
AR009600A1 (es) 2000-04-26
TR199900940T2 (xx) 1999-09-21
EE9900176A (et) 1999-12-15
AU734052B2 (en) 2001-05-31
NZ334568A (en) 2000-04-28
NO991995D0 (no) 1999-04-27
IL129397A0 (en) 2000-02-17
ID22065A (id) 1999-08-26
IS5005A (is) 1999-03-18
SA98180918A (ar) 2005-12-03
JP2001504329A (ja) 2001-04-03
AU5093398A (en) 1998-05-22
PL333169A1 (en) 1999-11-22
EP0973394A4 (en) 2005-03-30
SK34699A3 (en) 2000-04-10
WO1998018323A1 (en) 1998-05-07
EP0973394A1 (en) 2000-01-26
KR20000052831A (ko) 2000-08-25
CN1235513A (zh) 1999-11-17
NO991995L (no) 1999-06-28
BR9712587A (pt) 1999-10-26

Similar Documents

Publication Publication Date Title
JPH11513371A (ja) 肺炎球菌遺伝子、その一部、それ由来の発現産物、ならびに該遺伝子、該遺伝子の一部分、および該遺伝子産物の使用
WO1996040893A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
JP2002503683A (ja) 結核の免疫療法および診断のための化合物および方法
US20040052799A1 (en) Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
CA2265523A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
CA2269636A1 (en) C3 binding protein of streptococcus pneumoniae
JP3440221B2 (ja) アクチノバチルス・プレウロニウモニアからのタンパク質
US6716432B1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
US6528038B1 (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US20060246083A1 (en) Protective antigen of group a streptococci
US5595740A (en) Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
CA2248985A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
JPH09502604A (ja) Campylobacterjejuni抗原、並びにそれらの製造及び利用
AU8118598A (en) Immonogenic fragments of toxin a of clostridium difficile
JP2001510992A (ja) ヘリコバクター・ピロリに関連する核酸およびアミノ酸配列ならびにそのワクチン組成物
IL95578A (en) A vaccine made from polysaccharide and protein
AU762100B2 (en) Protective antigen of group A Streptococci (SPA)
US20040086524A1 (en) Vaccines and agents for inducing immunity in fish against rickettsial diseases, and associated preventative therapy
JP2004520825A (ja) ヘリコバクタータンパク質、核酸およびその使用
EP1535928B1 (en) Vaccine compositions comprising Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis
KR100216390B1 (ko) 헤모필루스 외부막 단백질
AU710880C (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
AU713844B2 (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
KR19990022600A (ko) 진단및치료용의헬리코박터피롤리관련핵산및아미노산서열
Joubert Expression of the botulinum neurotoxin serotype D binding domain in Brevibacillus brevis and its evaluation as a candidate vaccine antigen in mice

Legal Events

Date Code Title Description
FZDE Discontinued